Molecular Residual Disease in Solid Tumors [FH-PrwS-07-002]
Learning More About Molecular Residual Disease (MRD) in Solid Tumors
The purpose of this study is to learn more about molecular residual disease (MRD) in individuals diagnosed with early‑stage solid tumors. MRD refers to small amounts of cancer‑related genetic material that may remain in the body after treatment and are not detectable through standard imaging or routine tests. By studying MRD, researchers aim to better understand how tumor‑derived biomarkers, such as circulating tumor DNA, may provide insight into cancer detection, prognosis, treatment monitoring, and long‑term follow‑up. This study collects clinical information and biospecimens, including tumor samples and blood, from adults with solid tumors to support ongoing scientific efforts to explore how these biomarkers behave over time. The goal is to improve understanding of how MRD may help inform future approaches to cancer care, surveillance, and research.
The purpose of this study is to learn more about molecular residual disease (MRD) in individuals diagnosed with early‑stage solid tumors. MRD refers to small amounts of cancer‑related genetic material that may remain in the body after treatment and are not detectable through standard imaging or routine tests. By studying MRD, researchers aim to better understand how tumor‑derived biomarkers, such as circulating tumor DNA, may provide insight into cancer detection, prognosis, treatment monitoring, and long‑term follow‑up. This study collects clinical information and biospecimens, including tumor samples and blood, from adults with solid tumors to support ongoing scientific efforts to explore how these biomarkers behave over time. The goal is to improve understanding of how MRD may help inform future approaches to cancer care, surveillance, and research.
Disclaimer: This summary is informational and does not offer medical advice, suggest treatment benefits, or serve as a recruitment notice. Individuals seeking guidance regarding solid tumor care or monitoring should consult their healthcare provider.